🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Byooviz 10 mg/ml solution for injection

    Samsung Bioepis NL B.V.

    Neovascular Age-Related Macular Degeneration (AMD), Macular Oedema Secondary to Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV)

    phase 2 small molecule active

    1 trial

  2. C1 Esterase Inhibitor Injection [Cinryze]

    Takeda

    Subarachnoid Hemorrhage, Aneurysmal

    phase 2 small molecule active

    1 trial

  3. C16G2 Gel

    Armata Pharmaceuticals

    Dental Caries

    phase 2 small molecule completed

    1 trial

  4. C225 (cetuximab)

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  5. CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma.

    phase 2 small molecule active

    1 trial

  6. CABOZANTINIB, CABOZANTINIB, LANREOTIDE, CABOZANTINIB

    Fondazione Telethon ETS

    gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)

    phase 2 small molecule active

    1 trial

  7. CALCIUM FOLINATE , MK-2870, -, -, PARACETAMOL , MK-1022, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM LEVOFOLINATE , CAPECITABINE , -, MK-2870, FLUOROURACIL , OXALIPLATIN

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  8. CAP-1002 Allogeneic Cardiosphere-Derived Cells

    CAPRICOR THERAPEUTICS, INC.

    Myocardial Infarction

    phase 2 mab terminated

    1 trial

  9. CAPECITABINE , OXALIPLATIN

    Disc Medicine

    Patients with early-stage rectal cancer (defined as early rectal cancer cT1-3abN0M0 or early-intermediate rectal cancer cT1-3abN1(≤3 nodes ≤8mm)M0

    phase 2 small molecule active

    1 trial

  10. CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé, Capecitabine Accord 150 mg film-coated tablets, Oxaliplatin Bendalis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Capecitabin "Zentiva", filmovertrukne tabletter, Capecitabina Zentiva 500 mg compresse rivestite con film., Capecitabine Zentiva 150 mg filmdragerade tabletter, Capecitabin "Zentiva", filmovertrukne tabletter, CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé,

    GlaxoSmithKline

    MMRp/ MSS colon cancer

    phase 2 small molecule active

    1 trial

  11. CAPECITABINE, CAPECITABINE, NUBEQA 300 mg film-coated tablets

    Ningbo Cancer Hospital

    Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally recurrent (unresectable) or metastatic breast cancer.

    phase 2 small molecule active

    1 trial

  12. CAPECITABINE, Lonsurf 15 mg/6.14 mg film-coated tablets, FOLINIC ACID, FLUOROURACIL, OXALIPLATIN, NIVOLUMAB, Lonsurf 20 mg/8.19 mg film-coated tablets, LEVOLEUCOVORIN

    Ningbo Cancer Hospital

    Patients with HER 2 negative locally advanced, recurrent or metastatic gastric, oesophagus or gastroesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  13. CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance

    Daihong Liu

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

    phase 2 small molecule active

    1 trial

  14. CARBOPLATIN, ATEZOLIZUMAB, ETOPOSIDE, Ifinatamab deruxtecan

    Daiichi Sankyo

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  15. CAT-01

    The George Institute

    Cervical carcinoma

    phase 2 other active

    1 trial

  16. CBD Oral Solution (eCBD system Target)

    Jazz Pharmaceuticals Ireland Limited

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial

  17. CC-92480, Dexamethason acis 8 mg Tabletten, Dexamethason 8 mg JENAPHARM®, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, Dexamethason 4 mg JENAPHARM®, Dexamethason-ratiopharm® 4 mg Tabletten

    Celgene Europe Limited

    Relapsed and refractory multiple myeloma (RRMM)

    phase 2 small molecule active

    1 trial

  18. CC-97489, CC-97489, CC-97489 1mg , CC-97489 3mg

    Celgene Europe Limited

    Multiple Sclerosis Spasticity

    phase 2 small molecule active

    1 trial

  19. CCRT with Maintenance Tislelizumab and Metronomic Capecitabine

    BEONE MEDICINES AUS PTY LTD

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  20. CD123 targeted CAR-NK cells

    Chongqing Precision Biotech Co., Ltd

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  21. CD19 and CD22 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia, B-cell

    phase 2 mab active

    2 trials

  22. CD19 and CD22 targeted prime CAR- T cells

    Chongqing Precision Biotech Co., Ltd

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  23. CD19 and CD22 targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    B-ALL

    phase 2 mab active

    1 trial

  24. CD19 or CD20 CAR T cells briging HSCT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources